Get the Stockscreener App
16.65
0.63%
-0.75
Vtv Therapeutics Inc stock is traded at $16.65, with a volume of 40,243.
It is down -0.63% in the last 24 hours and up +22.28% over the past month.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
See More
Previous Close:
$17.40
Open:
$16.93
24h Volume:
40,243
Relative Volume:
1.34
Market Cap:
$41.41M
Revenue:
$5.02M
Net Income/Loss:
$-20.25M
P/E Ratio:
-69.38
EPS:
-0.24
Net Cash Flow:
$-19.08M
1W Performance:
+33.72%
1M Performance:
+22.28%
6M Performance:
-38.03%
1Y Performance:
+4,558%
1-Day Range:
$16.26
$17.19
1-Week Range:
$12.80
$18.31
52-Week Range:
$0.35
$30.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VTVT | 16.95 | 41.41M | 5.02M | -20.25M | -19.08M | -0.24 |
| VRTX | 467.45 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 760.78 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.72 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.44 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.44 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
vTv Therapeutics (NASDAQ:VTVT) shareholders are up 29% this past week, but still in the red over the last five years - Simply Wall St
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% - Yahoo Finance
Objective long/short (VTVT) Report - Stock Traders Daily
vTv Therapeutics (FRA:5VT0) 5-Year EBITDA Growth Rate : 25.50% (As of Jun. 2024) - GuruFocus.com
VTv Therapeutics: Q3 Earnings Snapshot - Darien Times
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire
(VTVT) Investment Analysis - Stock Traders Daily
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
How the (VTVT) price action is used to our Advantage - Stock Traders Daily
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
VTv Therapeutics : Termination of Material Agreement Form 8 K - Marketscreener.com
VTv Therapeutics: Q2 Earnings Snapshot - Barchart
Alzheimer's disease Market Size in the 7MM was ~USD 3,500 Million in 2022 | DelveInsight - openPR
Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily
Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight - Barchart
Alzheimer’s Disease Treatment Market Trends As Discussed In New Market Research Report - WhaTech
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Views of Wall Street’s Leading Experts on Volcon Inc - SETE News
Travere Therapeutics Inc (TVTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Valvoline Inc [VVV] Insider Activity: An Update for Investors - Knox Daily
Ventyx Biosciences Inc (VTYX) looking to reclaim success with recent performance - SETE News
What is going on with VCHA? Cancellations, member hiatus and more - MSN
Vital Energy Inc. (VTLE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Vanguard Total Corporate Bond Fund (NASDAQ:VTC) Reaches New 52-Week High at $79.92 - MarketBeat
VTYX overperforms with a 2.18 increase in share price - US Post News
VTLE’s latest rating updates from top analysts. - Knox Daily
TV’s 2023 Market Dance: Down -32.71% – Time to Invest? - The InvestChronicle
Texas Permanent School Fund Corp Sells 9,072 Shares of Veralto Co. (NYSE:VLTO) - Defense World
Learn to Evaluate (VTVT) using the Charts - Stock Traders Daily
Travere Therapeutics Inc [TVTX] Shares Rise 2.94 % on Thursday - Knox Daily
Neighbors concerned with proposed hospital in Webster Groves - KTVI Fox 2 St. Louis
When (VTVT) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate - Yahoo Finance
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 45.9% - Defense World
VTVT (vTv Therapeutics) Operating Cash Flow per Share : $-6.50 (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Free Cash Flow : $-21.81 Mil (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Change In Receivables : $-0.20 Mil (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Cyclically Adjusted Book per Share : $-228.01 (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Short-Term Capital Lease Obligation : $0.18 Mil (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Revenue per Share : $0.24 (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Ending Cash Position : $45.53 Mil (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Net Income From Continuing Operatio - GuruFocus.com
VTVT (vTv Therapeutics) Cash from Discontinued Operating Ac - GuruFocus.com
VTVT (vTv Therapeutics) GF Value Rank : 1 (As of Aug. 15, 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Liabilities-to-Assets : 0.56 (As of Jun. 2024) - GuruFocus.com
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):